Lackluster Fostamatinib Results Prompt AstraZeneca To Drop Rigel Deal

 
• By Lisa LaMotta

Disappointing Phase III results have pushed AstraZeneca to end yet another partnership, leaving Rigel in a tough spot as the biotech considers how to move forward now that its largest partner has jumped ship.

More from Clinical Trials

More from R&D